T1	Participants 51 82	acute myeloid leukemia patients
T2	Participants 547 696	newly diagnosed AML patients from 2 large study groups (the German AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group)
T3	Participants 1251 1283	261 patients from a third cohort
